Reprogramming T Cells And Reducing Manufacturing Costs With RegCell’s Michael McCullar, Ph.D.
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Reprogramming T Cells And Reducing Manufacturing Costs With RegCell’s Michael McCullar, Ph.D.
-
Narrated by:
-
Written by:
About this listen
In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell’s origins and its disease-agnostic approach to product development, as well as the ongoing efforts to improve the commercial viability of cell therapies by reducing manufacturing costs through automation and point-of-care models.
Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/
Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/
Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions
No reviews yet